Posterıor reversıble leukoencephalopathy syndrome developıng secondary tosunıtınıb therapy ın a patıent wıth metastatıc renal cell carcınoma
Küçük Resim Yok
Tarih
2018
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Carbone edıtore, vıa quıntıno sella, 68, palermo, 90139, ıtaly
Erişim Hakkı
info:eu-repo/semantics/restrictedAccess
Özet
Posterior reversible encephalopathy syndrome (PRES) is characterized by vasogenic edema occurring generally in parietal and occipital areas of the brain as a result of different etiologic causes and it is diagnosed by means of clinical and radiologic assessment. Sunitinib is an orally administered tyrosine kinase inhibitor used in the treatment of renal cell carcinoma with its antiangiogenic and antitumor effects. Fatigue, nausea-vomiting, diarrhea, hypertension, cardiotoxicity, hypothyroidism, neutropenia, and skin toxicity are among common side effects associated with sunitinib therapy. The current report presents a female patient with metastatic papillary renal cell cancer who developed posterior reversible encephalopathy syndrome as determined by means of clinical and radiologic assessment at 8 months of sunitinib therapy and who completely recovered with antihypertensive, antiepileptic, and antiedema therapy.
Açıklama
Anahtar Kelimeler
Cancer
Kaynak
Acta medıca medıterranea
WoS Q Değeri
Scopus Q Değeri
Cilt
34
Sayı
1
Künye
Kaplan, NB. Harputluoglu, H. Dikilitas, M. Elkiran, ET. Temelli, O. (2018).
Posterıor reversıble leukoencephalopathy syndrome developıng secondary tosunıtınıb therapy ın a patıent wıth metastatıc renal cell carcınoma. Cilt:34. Sayı:1. 39-42 ss.
